Tomas Olsson Selected Research

Retinaldehyde (Retinal)

11/2019	Retinal nerve fiber layer thickness associates with cognitive impairment and physical disability in multiple sclerosis.
1/2017	The Temporal Retinal Nerve Fiber Layer Thickness Is the Most Important Optical Coherence Tomography Estimate in Multiple Sclerosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tomas Olsson Research Topics

Disease

142	Multiple Sclerosis 02/2024 - 03/2002
30	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2021 - 07/2002
21	Inflammation (Inflammations) 01/2022 - 03/2003
20	Autoimmune Diseases (Autoimmune Disease) 02/2024 - 09/2003
16	Relapsing-Remitting Multiple Sclerosis 08/2023 - 02/2003
16	Neuroinflammatory Diseases 12/2020 - 12/2002
12	Disease Progression 02/2024 - 09/2003
12	Infections 12/2023 - 09/2009
10	Demyelinating Diseases (Demyelinating Disease) 01/2020 - 07/2002
9	Epstein-Barr Virus Infections 12/2021 - 09/2012
8	Progressive Multifocal Leukoencephalopathy 05/2021 - 09/2009
7	Obesity 10/2021 - 03/2014
6	Genetic Predisposition to Disease (Genetic Predisposition) 01/2022 - 05/2005
5	Infectious Mononucleosis (Glandular Fever) 01/2021 - 09/2014
5	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2020 - 01/2015
5	Postpoliomyelitis Syndrome (Post-Polio Syndrome) 07/2012 - 12/2002
4	Narcolepsy 01/2023 - 05/2014
4	Genetic Risk Score 11/2020 - 10/2016
4	Rheumatoid Arthritis 01/2020 - 05/2005
4	Encephalomyelitis (Myeloencephalitis) 04/2009 - 07/2003
3	COVID-19 12/2023 - 01/2021
3	Pain (Aches) 08/2023 - 07/2012
3	Congenital heart block 01/2022 - 01/2005
3	Alzheimer Disease (Alzheimer's Disease) 01/2021 - 01/2016
3	Dementia (Dementias) 01/2021 - 01/2019
3	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2021 - 05/2011
3	Cognitive Dysfunction 01/2021 - 11/2019
3	Pediatric Obesity 01/2021 - 01/2016
3	Neoplasms (Cancer) 01/2020 - 09/2010
3	Human Influenza (Influenza) 10/2017 - 05/2014
3	Central Nervous System Diseases (CNS Diseases) 12/2016 - 10/2013
3	Nervous System Diseases (Neurological Disorders) 05/2014 - 09/2010
3	Poliomyelitis (Polio) 03/2006 - 12/2002
2	Psychotic Disorders (Schizoaffective Disorder) 10/2023 - 11/2020
2	Fatigue 02/2023 - 03/2016
2	Polyneuropathies (Polyneuropathy) 01/2023 - 12/2012
2	Guillain-Barre Syndrome 01/2023 - 12/2012
2	Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) 01/2023 - 12/2012
2	Atrioventricular Block 01/2022 - 01/2005
2	Measles 01/2022 - 07/2015
2	Prostatic Neoplasms (Prostate Cancer) 04/2021 - 05/2012
2	Vitamin D Deficiency 04/2020 - 12/2010

Drug/Important Bio-Agent (IBA)

24	Biomarkers (Surrogate Marker)IBA 02/2024 - 01/2009
22	Myelin-Oligodendrocyte GlycoproteinIBA 01/2019 - 07/2002
21	Proteins (Proteins, Gene)FDA Link 10/2023 - 09/2003
19	AntibodiesIBA 10/2023 - 10/2007
18	Vitamin D FDA LinkGeneric 02/2024 - 09/2010
18	Natalizumab (Tysabri)FDA Link 01/2023 - 09/2009
16	AutoantibodiesIBA 01/2022 - 09/2003
13	HLA-DRB1 Chains (HLA DRB1)IBA 01/2024 - 03/2014
12	Immunoglobulin G (IgG)IBA 01/2022 - 06/2012
11	AntigensIBA 01/2021 - 06/2008
11	HLA Antigens (Human Leukocyte Antigens)IBA 01/2021 - 03/2011
9	CytokinesIBA 01/2019 - 11/2002
8	Oligoclonal BandsIBA 12/2016 - 01/2013
7	Messenger RNA (mRNA)IBA 12/2023 - 12/2002
7	Peptides (Polypeptides)IBA 01/2017 - 02/2003
5	Fingolimod Hydrochloride (FTY720)FDA Link 12/2023 - 12/2014
5	Rituximab (Mabthera)FDA Link 11/2022 - 04/2011
5	AutoantigensIBA 04/2022 - 10/2003
5	EBV-encoded nuclear antigen 1IBA 12/2021 - 01/2020
5	HLA-A Antigens (HLA-A)IBA 11/2020 - 09/2012
5	LigandsIBA 08/2016 - 09/2007
5	EpitopesIBA 10/2015 - 01/2005
4	ORALIT (ORS)IBA 01/2024 - 01/2020
4	VaccinesIBA 12/2023 - 01/2016
4	Blood Proteins (Serum Proteins)IBA 01/2022 - 12/2011
4	Myelin Basic ProteinIBA 01/2021 - 02/2003
4	SolventsIBA 01/2019 - 01/2016
4	Complement System Proteins (Complement)IBA 01/2015 - 10/2007
4	Intravenous Immunoglobulins (IVIG)FDA Link 07/2012 - 05/2004
3	hydroxide ionIBA 02/2024 - 04/2013
3	Glatiramer Acetate (Copaxone)FDA Link 01/2023 - 01/2015
3	InterferonsIBA 01/2023 - 10/2020
3	OrexinsIBA 01/2023 - 05/2014
3	Interferon-betaIBA 01/2022 - 11/2014
3	HLA-DR15 antigenIBA 01/2021 - 01/2018
3	Interleukin-22 (IL-22)IBA 01/2019 - 12/2010
3	LipidsIBA 11/2017 - 06/2012
3	DNA (Deoxyribonucleic Acid)IBA 01/2017 - 02/2003
3	OsteopontinIBA 08/2016 - 01/2011
3	ChemokinesIBA 08/2016 - 10/2003
3	Interleukin-7 (Interleukin 7)IBA 11/2014 - 09/2007
3	Monoclonal AntibodiesIBA 12/2012 - 04/2011
3	Immunoglobulins (Immunoglobulin)IBA 06/2012 - 12/2006
3	MHC class II transactivator proteinIBA 07/2009 - 05/2005
2	25-hydroxyvitamin DIBA 02/2024 - 09/2014
2	Tobacco Smoke Pollution (Passive Smoking)IBA 01/2023 - 12/2014
2	ponesimodIBA 01/2022 - 11/2014
2	SmokeIBA 01/2022 - 07/2014
2	Prostate-Specific Antigen (Semenogelase)IBA 04/2021 - 05/2012
2	Amyloid (Amyloid Fibrils)IBA 01/2021 - 01/2021
2	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2021 - 08/2010
2	7- (6- fluoropyridin- 3- yl)- 5H- pyrido(4,3- b)indoleIBA 01/2021 - 01/2021
2	Dimethyl FumarateIBA 10/2020 - 12/2019
2	Retinaldehyde (Retinal)IBA 11/2019 - 01/2017
2	Integrin alpha4beta1 (VLA-4)IBA 01/2019 - 04/2014
2	Coffee FDA Link 01/2019 - 01/2017

Therapy/Procedure

20	Therapeutics 12/2023 - 04/2011
2	Immunotherapy 08/2023 - 12/2015